Generally, certain molecular pathways, including phosphoinoisitide dependent kinase l, mTOR-RICTOR kinases and PI3K-AKT, could be affected or controlled by HIF-1α, which is itself an attractive drug target for clinical tumor treatment [22, 23]. This evidence concerns the gene AKT1 and neoplasm.